We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 89

Proposed new regulations for PMNOC proceedings and CSPs
  • Bereskin & Parr LLP
  • Canada
  • August 2 2017

On July 15 2017 the government published proposed new regulations to change the procedure under the Patented Medicines (Notice of Compliance


Proposed New Regulations for PM(NOC) Proceedings
  • Bereskin & Parr LLP
  • Canada
  • July 17 2017

On July 15, 2017 the government published proposed new Regulations to change the procedure under the Patented Medicines (Notice of Compliance


Memorandum: Case summary for Pfizer v Canada (2014 FC 1243, 2016 FCA 248)
  • Bereskin & Parr LLP
  • Canada
  • June 26 2017

The Federal Court of Appeal decision in Pfizer v. Canada (2016 FCA 248) upheld the Minister of Health’s interpretation that the 24-month stay for


Range in dosage regimen claims found not to invoke physician’s judgement
  • Bereskin & Parr LLP
  • Canada
  • April 17 2017

There has been a significant amount of uncertainty in Canada regarding the patentability of use claims which include dosages and dosage regimens


Tribunal Decides in Favour of Canada in NAFTA Arbitration Suit
  • Bereskin & Parr LLP
  • Canada
  • March 21 2017

The Government of Canada has prevailed in its NAFTA arbitration suit with Eli Lilly and Company “Lilly”. Lilly sued the sued the government as a


The Requirement of Causation in an Accounting of Profits - Federal Court of Appeal rules on Availability of Non-Infringing Alternatives and Apportionment of Non-Infringing Services
  • Bereskin & Parr LLP
  • Canada
  • March 16 2017

In a recent patent Accounting of profits decision of the Federal Court of Appeal in Apotex Inc v ADIR, 2017 FCA 23, the Court emphasized that the


Litigation - 2016 Year in Review
  • Bereskin & Parr LLP
  • Canada
  • March 8 2017

In 2016, the Federal government proposed changes to the rules that govern litigation, the Federal Courts issued directions for the conduct of


Ongoing Infringement Must be Parsed to Determine Relevant Limitation Periods
  • Bereskin & Parr LLP
  • Canada
  • January 24 2017

In the recent decision of Apotex Inc v AstraZeneca Canada Inc 2017 FCA 9 relating to the drug omeprazole, the Federal Court of Appeal held that in


Cialis Canadian Patent Knocks Out Double Patenting Challenge
  • Bereskin & Parr LLP
  • Canada
  • January 20 2017

Eli Lilly's Canadian patent on treatment of erectile dysfunction with Cialis continues to defy all challengers. A recent appeal case originated from


We Promise that it is Still Worthwhile to File Pharma Patents in Canada
  • Bereskin & Parr LLP
  • Canada
  • November 10 2016

The “promise doctrine” is getting a lot of press in the pharma industry. We know that some big pharma companies are ticked off, for example, from Eli